Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 4
2019 4
2020 2
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Ichikawa H, Sakai H, Hojo W, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: nagao s. Vaccines (Basel). 2022 Oct 29;10(11):1830. doi: 10.3390/vaccines10111830. Vaccines (Basel). 2022. PMID: 36366338 Free PMC article.
Safety and Accuracy of Professional Continuous Glucose Monitoring in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nagao S, Yakushijin K, Higashime A, Kawaguchi K, Watanabe M, Sakai R, Ichikawa H, Mizutani Y, Goto H, Kakiuchi S, Kurata K, Kitao A, Miyata Y, Imamura Y, Hirota Y, Takahashi M, Kawamoto S, Yamamoto K, Matsuoka H, Minami H. Nagao S, et al. Blood Cell Ther. 2023 Mar 24;6(2):54-60. doi: 10.31547/bct-2022-024. eCollection 2023 May 25. Blood Cell Ther. 2023. PMID: 37342353 Free PMC article.
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: nagao s. Vaccines (Basel). 2022 Jan 21;10(2):158. doi: 10.3390/vaccines10020158. Vaccines (Basel). 2022. PMID: 35214617 Free PMC article.
Global longitudinal strain is superior to ejection fraction for long-term follow-up after allogeneic hematopoietic stem cell transplantation.
Watanabe M, Yakushijin K, Tanaka H, Chijiki R, Saeki M, Hirakawa Y, Takakura H, Usui Y, Ichikawa H, Sakai R, Matsumoto S, Nagao S, Mizutani Y, Kurata K, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Matsuoka H, Minami H. Watanabe M, et al. Among authors: nagao s. EJHaem. 2022 Nov 7;4(1):192-198. doi: 10.1002/jha2.586. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819160 Free PMC article.
Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia.
Ichikawa H, Yakushijin K, Miyata Y, Kanehira H, Joyce M, Hirakawa Y, Matsumoto S, Nagao S, Sakai R, Kurata K, Kitao A, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Ichikawa H, et al. Among authors: nagao s. EJHaem. 2023 Jun 1;4(3):695-704. doi: 10.1002/jha2.728. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601886 Free PMC article.
GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.
Inase A, Maimaitili Y, Kimbara S, Mizutani Y, Miyata Y, Ohata S, Matsumoto H, Kitao A, Sakai R, Kawaguchi K, Higashime A, Nagao S, Kurata K, Goto H, Kawamoto S, Yakushijin K, Minami H, Matsuoka H. Inase A, et al. Among authors: nagao s. EJHaem. 2022 Dec 12;4(1):153-164. doi: 10.1002/jha2.600. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819180 Free PMC article.
Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.
Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F. Maekawa T, et al. Among authors: nagao s. Blood. 2019 Sep 5;134(10):814-825. doi: 10.1182/blood.2019000051. Epub 2019 Jul 3. Blood. 2019. PMID: 31270105 Free article.
[Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].
Teramoto M, Sone T, Takada K, Ogata H, Saito K, Izumi T, Takano K, Nagao S, Okada Y, Tachi N, Kawamura T, Kato S, Maekawa T, Kobayashi A, Kobayashi S, Sato K, Kimura F. Teramoto M, et al. Among authors: nagao s. Rinsho Ketsueki. 2020;61(6):598-604. doi: 10.11406/rinketsu.61.598. Rinsho Ketsueki. 2020. PMID: 32624531 Japanese.
13 results